Introduction to Interfacial Dynamics of Surfactants and Emulsifiers in PLGA Microsphere Fabrication The primary function of surfactants and emulsifiers in […]
Role of Surfactants and Emulsifiers in PLGA Microsphere Fabrication by Double Emulsion Read More »
Introduction: Naltrexone PLGA microsphere burst release is one of the most technically demanding problems in long-acting injectable (LAI) formulation science.
Naltrexone PLGA Microsphere Case Study: Controlling Burst Release Through Polymer Design Read More »
Introduction Sustained-release ocular drug delivery continues to represent a major bioengineering challenge because the eye possesses multiple anatomical and physiological
PLGA-Based Ocular Drug Delivery: Implants, Microspheres, and Injectable Systems Read More »
Introduction: Why the Erosion Mechanism Is Everything The most critical factor in PLGA formulation design is not particle size or
Bulk Erosion vs Surface Erosion in PLGA: How Degradation Mechanism Controls Drug Release Read More »
Introduction: For manufacturers pursuing approval of a generic PLGA-based injectable depot product, demonstrating PLGA polymer sameness for an ANDA submission
Introduction: Why Characterization of Long-Acting Biologics in PLGA Demands a Dedicated Framework The characterization of long-acting biologics encapsulated within poly(lactic-co-glycolic
Characterization of Long-Acting Biologics in PLGA Systems Read More »
Introduction The Glass Transition Temperature (Tg) of PLGA is far more than a routine material specification. It functions as the
Introduction: IVIVC for PLGA based Injectable Formulations has become increasingly important in the development of long-acting parenteral drug delivery systems.
In Vitro–In Vivo Correlation (IVIVC) for PLGA-Based Injectable Formulations Read More »
Introduction: When developing a next-generation injectable, implantable, or targeted therapy using poly(lactic-co-glycolic acid) (PLGA), one of the most consequential early
Introduction: Octreotide PLGA Characterization plays a pivotal role in the development and regulatory approval of generic long-acting injectable depots. For
